The First Asian, Single-Center Experience of Blastocyst Preimplantation Genetic Diagnosis with HLA Matching in Thailand for the Prevention of Thalassemia and Subsequent Curative Hematopoietic Stem Cell Transplantation of Twelve Affected Siblings.

Autor: Tiewsiri K; Superior A.R.T., 1126/2 Vanit Building II, New Petchburi Road, Makkasan, Ratchathewi, Bangkok 10400, Thailand., Manipalviratn S; Superior A.R.T., 1126/2 Vanit Building II, New Petchburi Road, Makkasan, Ratchathewi, Bangkok 10400, Thailand., Sutheesophon W; THAI StemLife, 566/3 Soi Ramkhamhaeng 39 (Thepleela 1), Prachaouthit Rd., Wangthonglang, Wangthonglang, Bangkok 10310, Thailand., Vanichsetakul P; Hematopoietic Stem Cell Transplant Unit, Wattanosoth Hospital, 2 Soi Soonvijai 7, New Petchburi Road, Huaykwang, Bangkok 10310, Thailand., Thaijaroen P; Superior A.R.T., 1126/2 Vanit Building II, New Petchburi Road, Makkasan, Ratchathewi, Bangkok 10400, Thailand., Ketcharoon P; Superior A.R.T., 1126/2 Vanit Building II, New Petchburi Road, Makkasan, Ratchathewi, Bangkok 10400, Thailand., Bradley CK; Genea, 321 Kent Street, Sydney, New South Wales 2000, Australia., McArthur SJ; Genea, 321 Kent Street, Sydney, New South Wales 2000, Australia., Krutsawad W; Superior A.R.T., 1126/2 Vanit Building II, New Petchburi Road, Makkasan, Ratchathewi, Bangkok 10400, Thailand., Marshall JTA; Superior A.R.T., 1126/2 Vanit Building II, New Petchburi Road, Makkasan, Ratchathewi, Bangkok 10400, Thailand., Papadopoulos KI; THAI StemLife, 566/3 Soi Ramkhamhaeng 39 (Thepleela 1), Prachaouthit Rd., Wangthonglang, Wangthonglang, Bangkok 10310, Thailand.
Jazyk: angličtina
Zdroj: BioMed research international [Biomed Res Int] 2020 Jun 26; Vol. 2020, pp. 5292090. Date of Electronic Publication: 2020 Jun 26 (Print Publication: 2020).
DOI: 10.1155/2020/5292090
Abstrakt: Results: In 221 cycles from 138 patients (104 cycles requiring HLA matching), 90.5% had embryo(s) biopsied for genetic testing. There were 119 embryo transfers for thalassemia (76) and thalassemia-HLA cases (43), respectively, resulting in overall clinical pregnancy rates of 54.6%, implantation rates of 45.7%, and live birth rates of 44.1%. Our dataset included fifteen PGD-HLA live births with successful HSCT in twelve affected siblings, 67% using umbilical cord blood stem cells (UCBSC) as the only SC source.
Conclusions: We report favorable thalassemia PGD and PGD-HLA laboratory and clinical outcomes from a single center. The ultimate success in PGD-HLA is of course the cure of a thalassemia-affected sibling by HSCT. Our PGD-HLA HSCT series is the first and largest performed entirely in Asia with twelve successful and two pending cures and predominant UCBSC use.
Competing Interests: KT, PV, CKB, PT, PK and WK have nothing to disclose. SJM and JTAM are shareholders of Genea Ltd.; SM, WS and KIP are shareholders of companies related to Superior A.R.T.
(Copyright © 2020 Kasorn Tiewsiri et al.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje